Comprehensive Cell Solutions Capacity Update May 2024: Cell & Gene Therapy

Comprehensive Cell Solutions (CCS) is a CGT focused division of New York Blood Center Enterprises with a Draw-To-Thaw™ portfolio of CDMO services strategically located throughout the US built upon on NYBC’s 60+ years of experience.

Founded in 2003 as a business unit of New York Blood Center Enterprises, CCS offers its deep expertise in the development and manufacture of cell and gene therapies, using its GMP and GTP facilities. CCS provides a true vein-to-vein solution, spanning fresh cellular collections and cord blood-derived stem cells as source material, to cell isolation, manipulation and cryopreservation capabilities for preclinical to commercial stage products.

CCS boasts a client roster comprised of the world’s leading pharmaceutical companies, innovative biotechnology organizations, and academic medical centers. CCS maintains its headquarters in New York City, where it offers its full service CDMO capabilities from cellular collections and clinical apheresis through manufacturing and cryopreservation. Additional collection suites, apheresis services, and development and manufacturing operations are offered at sites in Providence, RI, Kansas City, MO, St. Paul, MN, Houston, TX and Louisville, KY.